Regional Comparisons
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Exclusive analyses of drug review trends, approval decisions and regulatory guidance across regions.
![](/-/media/editorial/pink-sheet/2024/07/ps_07_24_usveu_shutterstock_2101006339_1200.jpg?rev=453b5c188bb14c42a24daa4c2537af03&w=350&hash=E8AD99C4878998E43E2E90101A89A356)
Decoding Regulatory Agency Decisions: The Case of Amylyx’s Relyvrio/Albrioza in the US and EU
Relyvrio/Albrioza, Amylyx’s ill-fated treatment for amyotrophic lateral sclerosis, was approved for marketing by the US Food and Drug Administration but rejected by the European Medicines Agency. The Pink Sheet explores how the two agencies applied the available regulatory flexibilities and the impact of other factors, such as regulatory precedence and patient influence, on decision-making.
![](/-/media/editorial/pink-sheet/00_regular-column-images/pinksheet_podcast_1200.png?rev=bc6eb4e16393438f9391192abb7e54be&w=350&hash=52CA70D84C472F2FCD016F8FE66566D8)
Pink Sheet Podcast Special: Why The US Approves Most New Drugs Before The EU
Pink Sheet reporter and editors discuss the impact of a US and EU drug approvals analysis that found the US FDA still clears many novel products first, including most new cell and gene therapies and cancer treatments.
![](/-/media/editorial/pink-sheet/2024/07/ps2407_us-eu_topography_2261234821-1200.jpg?rev=00c20dd286bb4479be306cf6ccfa1adf&w=350&hash=EAFAA49AB6D089622D9197DE5812D1B9)
US FDA Offers Faster Route To Market Than EMA: Details On All 108 Approvals
Comprehensive table comparing all the novel agents approved by either the US FDA or the European Commission over 2023 through April 2024.
![](/-/media/editorial/pink-sheet/2024/07/ps2407_us-eu-time-sign-post_209149840_1200.jpg?rev=c771464a28a14393b81406cd9c0e9060&w=350&hash=BA301C9A8EAED86B0829ABD13B88BB62)
Approval Geography: Novel Agent Landscape Across US And EU
Pink Sheet infographic shows how a large majority of novel drugs make it past the US FDA before receiving approval in the European Union. Lag times ranged from almost five years to less than two weeks.
![](/-/media/editorial/pink-sheet/2024/07/ps2407_cancer-ribbons_1886230204-1200.jpg?rev=60262726ad6741e49043561a81744ca1&w=350&hash=3EDF3F7437AB9756492785C69ADC4D97)
New Oncologics Overwhelmingly Approved In US Before EU
Ninety-five percent of novel cancer treatments approved in both the US and Europe received the FDA’s OK first, but Europe usually followed within a year, a Pink Sheet analysis shows.
![](/-/media/editorial/pink-sheet/2024/07/ps2407_us-eu-genetic-sequencing_2331315969-1200.jpg?rev=e5dd12e0f37f453fa453d849144e6a9b&w=350&hash=A20B70BA52AF190E1A87D7210A4AC6F4)
Getting To Global Is A Hurdle For Cell And Gene Therapies
Only three of the 10 new therapies approved by the US FDA also have been approved in the European Union, while both of the EU gene therapy approvals followed FDA clearance, a Pink Sheet analysis shows.
![](/-/media/editorial/pink-sheet/2024/07/ps240705_eu-fda-approvals-highways_2267913397-1200.jpg?rev=185a32428ed04310a944d51b39ae18f5&w=350&hash=7C90F02F102E7EEF085D276E7DCC0F60)
Pharma Looks To America First: US FDA Holds Overwhelming Lead Over EMA In Novel Approvals
A Pink Sheet analysis finds US approval preceded European Union clearance for 80% of products approved in both areas, but when EU approval came first, it beat the FDA by a median of 13 months. US-first approvals came close to six months before the EU.
![](/-/media/editorial/pink-sheet/2024/06/ps2406_global_526255060_1200.jpg?rev=db7128afcdad46e594d564b147fef3b3&w=350&hash=CE0F0ECF5254557BDBEAEFB5F1D218CB)
Project Orbis, 'Cluster' Calls Validate Global Regulators’ Drug Application Concerns
Regulators from the US, Canada, European Union, Switzerland and Japan talk about the benefits of global collaboration, and reasons why they might reach different decisions on the same drug, at the American Society of Clinical Oncology annual meeting.
![](/-/media/editorial/pink-sheet/2024/03/ps2403_us_eu_chess_792494191_1200.jpg?rev=a850482ff0ce435282c64fce58da0f20&w=350&hash=AB07A49DF10BE6B016A8F5B9B71A7585)
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.
![](/-/media/editorial/generics/2024/03/gb2403_business_decision_1151595443_1200.jpg?rev=a6b643e73c1d468aadc1cd0b42c921c5&w=350&hash=C1A2C3F48B9732E0E23636294993985E)
For Generics, EU Reference Product Is Non-Negotiable – Even In Pilot On Parallel Advice
Acknowledging that it may be a barrier to some extent, EMA’s senior scientific specialist of clinical pharmacology Kevin Blake notes that EU reference medicinal products are a legal requirement for bioequivalence studies and cannot be circumvented.
![](/-/media/editorial/medtech-insight/2023/06/mt2306_ailaw_1200.jpg?rev=1ad23df84b0d485f8f4f93a3d7db6d77&w=350&hash=597E3AFBC76FD55A3C648A2637C78DC1)
How The EU & UK’s Contrasting Approaches To AI Regulation Could Impact Pharma
While EU preparations are underway to introduce strict legal requirements for all AI systems, the UK has doubled down on its flexible, non-regulatory framework. In this second of a two-part article, a lawyer explains the pros and cons of each for pharma and medtech firms.
![](/-/media/editorial/pink-sheet/2024/02/ps2402_psychedelic-trippy_2214711703-1200.jpg?rev=917f5149abce41f3b762ed6e9834bcc7&w=350&hash=0EA86E121C9EF338040196027742645B)
For Psychedelics, US FDA Is Open To Creative Thinking But Firm On Approval Standards
Flexible thinking and rigorous standards will both be needed to develop psychedelics as drug therapies in order to surmount the many complicating factors, from unique ‘set and setting’ aspects to functional unblinding, speakers at Reagan-Udall Foundation meeting agree.
![](/-/media/editorial/generics/2024/02/gb2402_puzzle_pieces_men_us_eu_572835910_1200.jpg?rev=be74ab711f0942b98dddcd32eee36b8d&w=350&hash=1BD6CB3373AC5187C62AB929AEDF60CC)
FDA-EMA Pilot Advice Scheme On Complex Generics Sees Slow Uptake
While approaching the third year of its launch, the parallel advice program has seen a handful of applicants, but regulators on both sides of the Atlantic remain optimistic.
![](/-/media/editorial/pink-sheet/2024/01/ps2401_ps_networking_1467561665_1200.jpg?rev=33f45efa3b084981877dab0a84badbef&w=350&hash=B2AFE32025AB749E6C5DB0788263A209)
Regulatory Reliance Pathways: Challenges And Opportunities Ahead
International interest in fast-track regulatory reliance and collaboration pathways such as Project Orbis and the ACCESS Consortium has grown in recent years, a trend that looks set to continue in 2024. But some policy experts have warned that faster approvals are not always better, with one academic claiming the bar for marketing authorizations has dropped “far too low.”
![](/-/media/editorial/pink-sheet/2023/12/ps2312_globepills_1200.jpg?rev=398005a470b34c579436e9915b5f9edb&w=350&hash=C4266D350766FD7601BD07E56DB45C73)
Project Orbis 2023: FDA Approves Six New Cancer Drugs, But Partner Nations Lag Behind
Sixteen cancer therapies have been granted marketing authorizations or label variations in the US this year via the Project Orbis scheme. However, the majority of these are still under review by Orbis partners, which have also been outpaced by the non-Orbis EU.
![](/-/media/editorial/pink-sheet/2023/11/ps2311_us-vs-eu-review-times.jpg?rev=30028f8e6425462699fcae60f7ce5061&w=350&hash=21D51FCF02916F28752E9D29FEFDD570)
Watching The Clock Stop: US/EU Regulatory Review Time Parity In Sight, Study Suggests
European Union reform proposals could reduce ‘clock stop’ time in drug reviews, which a new study identified as the primary driver of longer review times at the EMA compared with the US FDA.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.